A long-term analysis of the FOLL05 trial found favorable outcomes at 8 years in advanced-stage follicular lymphoma patients treated with three different rituximab/chemotherapy combinations.
Elevated pre-transplant C-reactive protein was associated with worse overall survival in patients who underwent autologous stem cell transplantation for multiple myeloma, particularly in those who had transplant more than 12 months after diagnosis.
Integrating genetic risk factors with minimal residual disease improves the accuracy of risk stratification for children with acute lymphoblastic leukemia.
Treatment with bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia compared with treatment with imatinib.
The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients. This marks the first approval from the agency for treating this rare blood cancer.
The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity in patients with relapsed/refractory multiple myeloma.
In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.
Researchers have developed a model that has prognostic value in predicting favorable or unfavorable responses to immunomodulatory derivatives in patients with multiple myeloma.
Characteristics of the diabetic intrauterine environment may promote the development of acute lymphoblastic leukemia in offspring, according to the results of a new study.